ABT-436
Clinical data | |
---|---|
Routes of administration | By mouth |
Identifiers | |
CAS Number | |
UNII |
ABT-436 is an
V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued.[1][2][3] It reached phase II clinical trials prior to the discontinuation of its development.[1][3]
See also
- Balovaptan
- Nelivaptan
- SRX-246
- TS-121
References
- ^ a b "ABT 436". AdisInsight. Springer Nature Switzerland AG.
- ^ Wernet W, Hornberger WB, Unger LV, Meyer AH, Netz PA, Oost T, et al. (2008). In vitro characterization of the selective vasopressin V1b receptor antagonists ABT-436 and ABT-558. Proceedings of Society for Neuroscience. Washington DC, USA. p. Abstract 560.
- ^ PMID 27658483.